APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Stromal Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Gastrointestinal Stromal Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025197 pages

Choose your research edition.

Industry ResearchGastrointestinal Stromal Tumor Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Stromal Tumor Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Stromal Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Stromal Tumor Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Stromal Tumor Drug Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Gastrointestinal Stromal Tumor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Gastrointestinal Stromal Tumor Drug include China Biopharmaceuticals, Zai Lab, CSPC Pharmaceuticals, Novartis, Mylan Pharms Inc., Kelun Pharmaceuticals, CStone Pharmaceuticals, Hansoh Pharmaceuticals and Vannsh Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gastrointestinal Stromal Tumor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastrointestinal Stromal Tumor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastrointestinal Stromal Tumor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastrointestinal Stromal Tumor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastrointestinal Stromal Tumor Drug Segment by Company

China Biopharmaceuticals

Zai Lab

CSPC Pharmaceuticals

Novartis

Mylan Pharms Inc.

Kelun Pharmaceuticals

CStone Pharmaceuticals

Hansoh Pharmaceuticals

Vannsh Life Sciences

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceuticals

MSN Laboratories

Glenmark Pharmaceuticals Ltd.

Drug International

Dr. Reddy's Laboratories

Deciphera Pharmaceuticals

Bulat Pharmaceutical

Beacon Pharmaceuticals

Bayer Pharmaceuticals

Apotex Inc.

Actavis Generics

Gastrointestinal Stromal Tumor Drug Segment by Type

Ripretinib

Regorafenib

Sunitinib

Imatinib

Others

Gastrointestinal Stromal Tumor Drug Segment by Application

Hospital

Clinic

Others

Gastrointestinal Stromal Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastrointestinal Stromal Tumor Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Gastrointestinal Stromal Tumor Drug Industry Trends Table 2. Gastrointestinal Stromal Tumor Drug Industry Drivers Table 3. Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges Table 4. Gastrointestinal Stromal Tumor Drug Industry Restraints Table 5. Global Gastrointestinal Stromal Tumor Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Gastrointestinal Stromal Tumor Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers Table 9. Global Gastrointestinal Stromal Tumor Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Gastrointestinal Stromal Tumor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Gastrointestinal Stromal Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Gastrointestinal Stromal Tumor Drug Manufacturers, Product Type & Application Table 13. Global Gastrointestinal Stromal Tumor Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastrointestinal Stromal Tumor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ripretinib Table 17. Major Manufacturers of Regorafenib Table 18. Major Manufacturers of Sunitinib Table 19. Major Manufacturers of Imatinib Table 20. Major Manufacturers of Others Table 21. Global Gastrointestinal Stromal Tumor Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021-2026) Table 25. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2027-2032) Table 26. Global Gastrointestinal Stromal Tumor Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021-2026) Table 30. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Others Table 34. Global Gastrointestinal Stromal Tumor Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021-2026) Table 38. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2027-2032) Table 39. Global Gastrointestinal Stromal Tumor Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021-2026) Table 43. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2027-2032) Table 44. Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2021-2026) Table 47. Global Gastrointestinal Stromal Tumor Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Gastrointestinal Stromal Tumor Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Gastrointestinal Stromal Tumor Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2021-2026) Table 65. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2027-2032) Table 66. China Biopharmaceuticals Company Information Table 67. China Biopharmaceuticals Business Overview Table 68. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 70. China Biopharmaceuticals Recent Development Table 71. Zai Lab Company Information Table 72. Zai Lab Business Overview Table 73. Zai Lab Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio Table 75. Zai Lab Recent Development Table 76. CSPC Pharmaceuticals Company Information Table 77. CSPC Pharmaceuticals Business Overview Table 78. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 80. CSPC Pharmaceuticals Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio Table 85. Novartis Recent Development Table 86. Mylan Pharms Inc. Company Information Table 87. Mylan Pharms Inc. Business Overview Table 88. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 90. Mylan Pharms Inc. Recent Development Table 91. Kelun Pharmaceuticals Company Information Table 92. Kelun Pharmaceuticals Business Overview Table 93. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 95. Kelun Pharmaceuticals Recent Development Table 96. CStone Pharmaceuticals Company Information Table 97. CStone Pharmaceuticals Business Overview Table 98. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 100. CStone Pharmaceuticals Recent Development Table 101. Hansoh Pharmaceuticals Company Information Table 102. Hansoh Pharmaceuticals Business Overview Table 103. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 105. Hansoh Pharmaceuticals Recent Development Table 106. Vannsh Life Sciences Company Information Table 107. Vannsh Life Sciences Business Overview Table 108. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio Table 110. Vannsh Life Sciences Recent Development Table 111. Teva Pharmaceutical Industries Ltd. Company Information Table 112. Teva Pharmaceutical Industries Ltd. Business Overview Table 113. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 115. Teva Pharmaceutical Industries Ltd. Recent Development Table 116. Sun Pharmaceuticals Company Information Table 117. Sun Pharmaceuticals Business Overview Table 118. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 120. Sun Pharmaceuticals Recent Development Table 121. MSN Laboratories Company Information Table 122. MSN Laboratories Business Overview Table 123. MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio Table 125. MSN Laboratories Recent Development Table 126. Glenmark Pharmaceuticals Ltd. Company Information Table 127. Glenmark Pharmaceuticals Ltd. Business Overview Table 128. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 130. Glenmark Pharmaceuticals Ltd. Recent Development Table 131. Drug International Company Information Table 132. Drug International Business Overview Table 133. Drug International Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio Table 135. Drug International Recent Development Table 136. Dr. Reddy's Laboratories Company Information Table 137. Dr. Reddy's Laboratories Business Overview Table 138. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio Table 140. Dr. Reddy's Laboratories Recent Development Table 141. Deciphera Pharmaceuticals Company Information Table 142. Deciphera Pharmaceuticals Business Overview Table 143. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 145. Deciphera Pharmaceuticals Recent Development Table 146. Bulat Pharmaceutical Company Information Table 147. Bulat Pharmaceutical Business Overview Table 148. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio Table 150. Bulat Pharmaceutical Recent Development Table 151. Beacon Pharmaceuticals Company Information Table 152. Beacon Pharmaceuticals Business Overview Table 153. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 155. Beacon Pharmaceuticals Recent Development Table 156. Bayer Pharmaceuticals Company Information Table 157. Bayer Pharmaceuticals Business Overview Table 158. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 160. Bayer Pharmaceuticals Recent Development Table 161. Apotex Inc. Company Information Table 162. Apotex Inc. Business Overview Table 163. Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 165. Apotex Inc. Recent Development Table 166. Actavis Generics Company Information Table 167. Actavis Generics Business Overview Table 168. Actavis Generics Gastrointestinal Stromal Tumor Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio Table 170. Actavis Generics Recent Development Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Gastrointestinal Stromal Tumor Drug Distributors List Table 174. Gastrointestinal Stromal Tumor Drug Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Gastrointestinal Stromal Tumor Drug Product Image Figure 2. Global Gastrointestinal Stromal Tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Stromal Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Gastrointestinal Stromal Tumor Drug Sales (2021-2032) & (K Units) Figure 5. Global Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ripretinib Image Figure 9. Regorafenib Image Figure 10. Sunitinib Image Figure 11. Imatinib Image Figure 12. Others Image Figure 13. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Gastrointestinal Stromal Tumor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021-2032) Figure 16. Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Gastrointestinal Stromal Tumor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021-2032) Figure 25. Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 42. China Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Gastrointestinal Stromal Tumor Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Gastrointestinal Stromal Tumor Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Gastrointestinal Stromal Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Gastrointestinal Stromal Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Gastrointestinal Stromal Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Gastrointestinal Stromal Tumor Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Gastrointestinal Stromal Tumor Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ripretinib
  • Regorafenib
  • Sunitinib
  • Imatinib
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • China Biopharmaceuticals
  • Zai Lab
  • CSPC Pharmaceuticals
  • Novartis
  • Mylan Pharms Inc.
  • Kelun Pharmaceuticals
  • CStone Pharmaceuticals
  • Hansoh Pharmaceuticals
  • Vannsh Life Sciences
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceuticals
  • MSN Laboratories
  • Glenmark Pharmaceuticals Ltd.
  • Drug International
  • Dr. Reddy's Laboratories
  • Deciphera Pharmaceuticals
  • Bulat Pharmaceutical
  • Beacon Pharmaceuticals
  • Bayer Pharmaceuticals
  • Apotex Inc.
  • Actavis Generics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gastrointestinal Stromal Tumor Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gastrointestinal Stromal Tumor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Gastrointestinal Stromal Tumor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Gastrointestinal Stromal Tumor Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Gastrointestinal Stromal Tumor Drug Market Dynamics
  1. 2.1 Gastrointestinal Stromal Tumor Drug Industry Trends
  2. 2.2 Gastrointestinal Stromal Tumor Drug Industry Drivers
  3. 2.3 Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Stromal Tumor Drug Industry Restraints
3 Gastrointestinal Stromal Tumor Drug Market by Manufacturers
  1. 3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Gastrointestinal Stromal Tumor Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Gastrointestinal Stromal Tumor Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Gastrointestinal Stromal Tumor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Gastrointestinal Stromal Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Gastrointestinal Stromal Tumor Drug Manufacturers, Product Type & Application
  7. 3.7 Global Gastrointestinal Stromal Tumor Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Gastrointestinal Stromal Tumor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Gastrointestinal Stromal Tumor Drug Tier 1, Tier 2, and Tier 3
4 Gastrointestinal Stromal Tumor Drug Market by Type
  1. 4.1 Gastrointestinal Stromal Tumor Drug Type Introduction
  2. 4.1.1 Ripretinib
  3. 4.1.2 Regorafenib
  4. 4.1.3 Sunitinib
  5. 4.1.4 Imatinib
  6. 4.1.5 Others
  7. 4.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type
  8. 4.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Type
  12. 4.3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2021-2032)
5 Gastrointestinal Stromal Tumor Drug Market by Application
  1. 5.1 Gastrointestinal Stromal Tumor Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application
  6. 5.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Application
  10. 5.3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2021-2032)
6 Global Gastrointestinal Stromal Tumor Drug Sales by Region
  1. 6.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Gastrointestinal Stromal Tumor Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Gastrointestinal Stromal Tumor Drug Revenue by Region
  1. 7.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region
  2. 7.1.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Gastrointestinal Stromal Tumor Drug Revenue (2021-2032)
  8. 7.2.2 North America Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Gastrointestinal Stromal Tumor Drug Revenue (2021-2032)
  11. 7.3.2 Europe Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 China Biopharmaceuticals
  2. 8.1.1 China Biopharmaceuticals Company Information
  3. 8.1.2 China Biopharmaceuticals Business Overview
  4. 8.1.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  6. 8.1.5 China Biopharmaceuticals Recent Developments
  7. 8.2 Zai Lab
  8. 8.2.1 Zai Lab Company Information
  9. 8.2.2 Zai Lab Business Overview
  10. 8.2.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
  12. 8.2.5 Zai Lab Recent Developments
  13. 8.3 CSPC Pharmaceuticals
  14. 8.3.1 CSPC Pharmaceuticals Company Information
  15. 8.3.2 CSPC Pharmaceuticals Business Overview
  16. 8.3.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  18. 8.3.5 CSPC Pharmaceuticals Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Mylan Pharms Inc.
  26. 8.5.1 Mylan Pharms Inc. Company Information
  27. 8.5.2 Mylan Pharms Inc. Business Overview
  28. 8.5.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
  30. 8.5.5 Mylan Pharms Inc. Recent Developments
  31. 8.6 Kelun Pharmaceuticals
  32. 8.6.1 Kelun Pharmaceuticals Company Information
  33. 8.6.2 Kelun Pharmaceuticals Business Overview
  34. 8.6.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  36. 8.6.5 Kelun Pharmaceuticals Recent Developments
  37. 8.7 CStone Pharmaceuticals
  38. 8.7.1 CStone Pharmaceuticals Company Information
  39. 8.7.2 CStone Pharmaceuticals Business Overview
  40. 8.7.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  42. 8.7.5 CStone Pharmaceuticals Recent Developments
  43. 8.8 Hansoh Pharmaceuticals
  44. 8.8.1 Hansoh Pharmaceuticals Company Information
  45. 8.8.2 Hansoh Pharmaceuticals Business Overview
  46. 8.8.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  48. 8.8.5 Hansoh Pharmaceuticals Recent Developments
  49. 8.9 Vannsh Life Sciences
  50. 8.9.1 Vannsh Life Sciences Company Information
  51. 8.9.2 Vannsh Life Sciences Business Overview
  52. 8.9.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
  54. 8.9.5 Vannsh Life Sciences Recent Developments
  55. 8.10 Teva Pharmaceutical Industries Ltd.
  56. 8.10.1 Teva Pharmaceutical Industries Ltd. Company Information
  57. 8.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
  58. 8.10.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  61. 8.11 Sun Pharmaceuticals
  62. 8.11.1 Sun Pharmaceuticals Company Information
  63. 8.11.2 Sun Pharmaceuticals Business Overview
  64. 8.11.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  66. 8.11.5 Sun Pharmaceuticals Recent Developments
  67. 8.12 MSN Laboratories
  68. 8.12.1 MSN Laboratories Company Information
  69. 8.12.2 MSN Laboratories Business Overview
  70. 8.12.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
  72. 8.12.5 MSN Laboratories Recent Developments
  73. 8.13 Glenmark Pharmaceuticals Ltd.
  74. 8.13.1 Glenmark Pharmaceuticals Ltd. Company Information
  75. 8.13.2 Glenmark Pharmaceuticals Ltd. Business Overview
  76. 8.13.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
  78. 8.13.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  79. 8.14 Drug International
  80. 8.14.1 Drug International Company Information
  81. 8.14.2 Drug International Business Overview
  82. 8.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
  84. 8.14.5 Drug International Recent Developments
  85. 8.15 Dr. Reddy's Laboratories
  86. 8.15.1 Dr. Reddy's Laboratories Company Information
  87. 8.15.2 Dr. Reddy's Laboratories Business Overview
  88. 8.15.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
  90. 8.15.5 Dr. Reddy's Laboratories Recent Developments
  91. 8.16 Deciphera Pharmaceuticals
  92. 8.16.1 Deciphera Pharmaceuticals Company Information
  93. 8.16.2 Deciphera Pharmaceuticals Business Overview
  94. 8.16.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  96. 8.16.5 Deciphera Pharmaceuticals Recent Developments
  97. 8.17 Bulat Pharmaceutical
  98. 8.17.1 Bulat Pharmaceutical Company Information
  99. 8.17.2 Bulat Pharmaceutical Business Overview
  100. 8.17.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
  102. 8.17.5 Bulat Pharmaceutical Recent Developments
  103. 8.18 Beacon Pharmaceuticals
  104. 8.18.1 Beacon Pharmaceuticals Company Information
  105. 8.18.2 Beacon Pharmaceuticals Business Overview
  106. 8.18.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  108. 8.18.5 Beacon Pharmaceuticals Recent Developments
  109. 8.19 Bayer Pharmaceuticals
  110. 8.19.1 Bayer Pharmaceuticals Company Information
  111. 8.19.2 Bayer Pharmaceuticals Business Overview
  112. 8.19.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  114. 8.19.5 Bayer Pharmaceuticals Recent Developments
  115. 8.20 Apotex Inc.
  116. 8.20.1 Apotex Inc. Company Information
  117. 8.20.2 Apotex Inc. Business Overview
  118. 8.20.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
  120. 8.20.5 Apotex Inc. Recent Developments
  121. 8.21 Actavis Generics
  122. 8.21.1 Actavis Generics Company Information
  123. 8.21.2 Actavis Generics Business Overview
  124. 8.21.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
  126. 8.21.5 Actavis Generics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastrointestinal Stromal Tumor Drug Value Chain Analysis
  2. 9.1.1 Gastrointestinal Stromal Tumor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastrointestinal Stromal Tumor Drug Production Mode & Process
  6. 9.2 Gastrointestinal Stromal Tumor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastrointestinal Stromal Tumor Drug Distributors
  9. 9.2.3 Gastrointestinal Stromal Tumor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst